clindamycin phosphate
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
3854
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
December 13, 2025
Machine-Learning and Gene-Synergy Networks Reveal Interpretable Drivers of Antibiotic Resistance in Staphylococcus aureus.
(PubMed, Int J Antimicrob Agents)
- "Our findings indicate that antibiotic resistance in S. aureus involves distinct genetic network architectures depending on the antibiotic, highlighting the diverse regulatory pathways bacteria employ to acquire resistance. This discovery-oriented framework prioritizes interpretable determinants and generates testable mechanistic hypotheses, with prospective standardized evaluations aimed at assessing its translatability to clinical settings."
Journal
December 13, 2025
Janibacter melonis bacteremia following autologous stem cell mobilization in lymphoma: a case report and literature review.
(PubMed, BMC Infect Dis)
- "This case highlights the importance of considering rare infections in immunocompromised patients, especially those with hematologic malignancies. Prompt microbiological and molecular diagnosis, combined with targeted therapy, is essential for good outcomes. This report also provides useful insights for managing Janibacter melonis infections."
Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
December 05, 2025
Impact of broad-spectrum antibiotic exposure on outcomes following autologous stem cell transplantation for patients with relapsed diffuse large B-cell lymphoma or Hodgkin lymphoma
(ASH 2025)
- "Antibiotic exposure in the peri-transplant period was recorded, defined as receipt of greater than one day of: broad-spectrum intravenous antibiotics (cefepime, piperacillin-tazobactam, cephalosporins, or monobactams) or vancomycin. The BSA group was separately analyzed according to specific anaerobic coverage (metronidazole, carbapenems, piperacillin-tazobactam, or clindamycin) or not... In this retrospective cohort study of ASCT recipients, early exposure to BSA and AA were associated with decreased OS in univariate analysis, however in multivariate analysis only age remained significant. These findings suggest that while antibiotic exposure may correlate with outcomes, its effect is likely mediated by other clinical factors such as age, or may reflect underlying illness severity, rather than a direct causal relationship. Prospective studies are needed to clarify whether modification of antibiotic exposure can meaningfully improve long-term transplant outcomes without..."
Clinical • B Cell Lymphoma • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation
December 05, 2025
Acute Myeloid Leukemia patients with comorbid hidradenitis suppurativa maintain stable disease during induction therapy–induced neutropenia: A single-center retrospective study
(ASH 2025)
- "One patient received a short course of oral clindamycin for mild drainage without systemic symptoms... In AML patients with comorbid HS, induction therapy–induced neutropenia was not associated with worsening HS activity or related infectious complications. These findings suggest that hematologists can safely prioritize leukemia-directed treatment without concern for exacerbating HS during induction, and that a conservative, observation-focused approach to HS management is appropriate in this setting."
Retrospective data • Acute Myelogenous Leukemia • Dermatology • Hematological Disorders • Hematological Malignancies • Hidradenitis Suppurativa • Immunology • Infectious Disease • Leukemia • Neutropenia • Septic Shock
December 12, 2025
Antibacterial activity of Cerium Oxide Nanoparticles: a systematic review and meta-analysis study.
(PubMed, Nanomedicine (Lond))
- "Compared to conventional antibiotics, CeO2 NPs were generally less effective (SMD = -2.846, p < 0.0001) but performed comparably to Amoxicillin, Streptomycin, Linezolid, and Clindamycin. CeO2 NPs demonstrate significant broad-spectrum antibacterial activity, suggesting potential against antibiotic-resistant bacteria. Future research should explore synergistic effects with standard antibiotics."
Journal • Retrospective data • Review • Infectious Disease
December 12, 2025
P121 Treatment with semaglutide improves the systemic inflammatory burden associated with hidradenitis suppurativa.
(PubMed, Br J Dermatol)
- "The majority of patients (n = 54) had Hurley stage II disease, with 10 patients classified as Hurley stage III and 5 as Hurley stage I. Twenty-two patients were established on adalimumab with two on infliximab. Other biologics prescribed alongside semaglutide included brodalumab (n = 8) and secukinumab (n = 1). Nineteen patients were coprescribed metformin, and for 16 patients rescue antibiotics including rifampicin and clindamycin...Semaglutide can improve not only metabolic control, weight, flare frequency and quality of life, but also systemic inflammation and thus health outcomes (Lyons et al.). Although our findings did not reach statistical significance, the consistent trends observed in inflammatory markers and the established efficacy of semaglutide in weight loss and metabolic improvement suggest that it can enhance health outcomes for this patient population."
Journal • Retrospective data • Dermatology • Genetic Disorders • Hidradenitis Suppurativa • Immunology • Inflammation • Metabolic Disorders • Obesity • Systemic Inflammatory Response Syndrome
December 12, 2025
GD04 (P064) A study of multidrug resistance pattern in scabies-associated infections in endemic communities.
(PubMed, Br J Dermatol)
- "High resistance was noted for erythromycin (91.6%) and ciprofloxacin (53.7%). Gentamicin and clindamycin had moderate susceptibility rates of 57.4% and 51.9%, respectively. Nitrofurantoin and rifampicin maintained high susceptibility (98.1% and 92.6%). Among bacterial strains, methicillin-resistant S. aureus (MRSA) was most prevalent (46.3%), followed by coagulase-negative staphylococci (5.6%) and vancomycin-resistant S. aureus (5.6%)...The high prevalence of MRSA highlights the urgent need for improved infection control measures and the judicious use of antibiotics. While newer drugs like tigecycline, linezolid and daptomycin offer alternative treatment options, robust surveillance and targeted antibiotic stewardship programmes are crucial to address this growing challenge and ensure effective patient care.TableBacteria isolated from 55 patients with scabiesOrganism isolatedn (%)Staphylococcus aureus47 (97)Staphylococcus haemolyticus2 (4)Staphylococcus epidermidis2..."
Journal • Infectious Disease
December 12, 2025
P119 Serum complement, B cells and T cells as markers of treatment response in those treated with adalimumab and clindamycin-rifampicin for hidradenitis suppurativa: a pilot study.
(PubMed, Br J Dermatol)
- "Our patient numbers are small. If these findings are validated in a larger cohort this would begin to allow, for the first time, the personalization of treatment for HS."
Biomarker • Journal • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • CRP
December 12, 2025
Electrochemical detection of diclofenac and clindamycin using ZnO nanorods/RGO nanocomposite modified electrode.
(PubMed, RSC Adv)
- "The ZnO/RGO/GCE sensor was tested in a real sample of human urine and found a recovery range of 90.0% to 106.0%. Overall, the proposed dual electrochemical sensor can be used in real-world applications."
Journal
December 12, 2025
Prevalence, Antibiotic Resistance Pattern, and Molecular Characteristics of Staphylococcus epidermidis Isolated From Milk of Pure Breeds of Dairy Cattle With Subclinical Mastitis.
(PubMed, J Trop Med)
- "Our antibiogram results underscored a high resistance of S. epidermidis isolates, particularly against cefoxitin (56.25%) and penicillin (43.75%), while demonstrating remarkable susceptibility to amikacin (2.08%), clindamycin (0%), ciprofloxacin (0%), and chloramphenicol (0%). Further research is needed to examine geographic and farm-specific factors affecting S. epidermidis prevalence, and genetic techniques like multilocus sequence typing should be employed to study clonal spread and horizontal gene transfer. Routine antimicrobial sensitivity assessments and continuous monitoring of medication use are essential to develop sustainable strategies against antibiotic resistance in the dairy industry."
Journal • Gene Therapies • Inflammation
December 12, 2025
P064 A study of multidrug resistance pattern in scabies-associated infections in endemic communities.
(PubMed, Br J Dermatol)
- "High resistance was noted for erythromycin (91.6%) and ciprofloxacin (53.7%). Gentamicin and clindamycin had moderate susceptibility rates of 57.4% and 51.9%, respectively. Nitrofurantoin and rifampicin maintained high susceptibility (98.1% and 92.6%). Among bacterial strains, methicillin-resistant S. aureus (MRSA) was most prevalent (46.3%), followed by coagulase-negative staphylococci (5.6%) and vancomycin-resistant S. aureus (5.6%)...The high prevalence of MRSA highlights the urgent need for improved infection control measures and the judicious use of antibiotics. While newer drugs like tigecycline, linezolid and daptomycin offer alternative treatment options, robust surveillance and targeted antibiotic stewardship programmes are crucial to address this growing challenge and ensure effective patient care.TableBacteria isolated from 55 patients with scabiesOrganism isolatedn (%)Staphylococcus aureus47 (97)Staphylococcus haemolyticus2 (4)Staphylococcus epidermidis2..."
Journal • Infectious Disease
December 12, 2025
Necrotising soft tissue infection following myomectomy: a devastating postoperative complication.
(PubMed, BMJ Case Rep)
- "Despite receiving prophylactic clindamycin at the index surgery, her postoperative course was complicated by an abdominal wall abscess as well as necrotising soft tissue infection involving the uterus...Limited data support a need for further high-quality clinical trials to develop decisive guidance regarding antibiotic prophylaxis at the time of myomectomy. As demonstrated in this case, the consequences have the potential to lead to infertility, menopause and even death."
Journal • Gynecology • Infectious Disease • Infertility • Obstetrics • Sexual Disorders • Uterine Leiomyoma • Women's Health
December 11, 2025
Penicillin remains an effective agent against Group A Streptococcus in low- and middle-income countries: A systematic review and meta-analysis of antibiotic resistance and associated genes.
(PubMed, S Afr Med J)
- "This review comprehensively characterises the latest evidence on the prevalence of antibiotic resistance in Strep A in LMICs. Strep A in LMICs continues to be highly susceptible to antibiotics in vitro, primarily to penicillins. Strep A macrolide resistance patterns in LMICs are similar to those observed in high-income countries. The findings of this review may serve to inform effective treatment decisions and public health interventions."
Clinical • Journal • Retrospective data • Review
December 11, 2025
Two Independent Acquisitions of Multidrug Resistance Gene lsaC in Streptococcus pneumoniae Serotype 20 Multilocus Sequence Type 1257.
(PubMed, Emerg Infect Dis)
- "Among >25,000 invasive pneumococcal disease isolates recovered in US locations during 2015-early 2024 through population-based surveillance, we detected 17 case isolates carrying the lsaC gene, which has been shown to confer resistance to clindamycin in group B Streptococcus...All 17 lsaC-positive isolates shared a 5.2-kb lsaC-containing element precisely integrated within the conserved oriT site of their respective mobile element. Those 17 lsaC-positive strains were all serotype 20, multilocus sequence type 1257, and were recovered recently (2021-2024); isolates 1-16 represented emergent disease clusters in New York and Connecticut."
Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Substance Abuse
December 11, 2025
Characterization and Genomic Analysis of Pasteurella multocida NQ01 Isolated from Yak in China.
(PubMed, Animals (Basel))
- "Antimicrobial testing showed broad susceptibility to β-lactams, aminoglycosides, tetracyclines, fluoroquinolones, midecamycin, florfenicol, polymyxin, and vancomycin, with resistance to metronidazole, trimethoprim sulfamethoxazole, and clindamycin. Phylogenetically, NQ01 clusters with regional B:2 bovine/yak isolates. Collectively, these data define NQ01 as a highly virulent, low-resistance yak isolate and a practical model for natural-route HS pathogenesis and targeted control in high-altitude pastoral settings yaks."
Journal • CNS Disorders • Hematological Disorders • Immune Modulation • Immunology • Infectious Disease • Otorhinolaryngology • NQO1
December 11, 2025
Patient with Inflammatory Bowel Disease in a Dental Office-Which Antibiotic to Choose?-Narrative Review.
(PubMed, J Clin Med)
- " The available evidence suggests that first- and second-line dental antibiotics-amoxicillin, ampicillin, and clindamycin-carry the highest risk of CDI. Tailored, microbiome-conscious antibiotic strategies are essential in dental management of IBD patients. Further clinical research is needed to develop evidence-based guidelines and validate promising adjunctive approaches."
Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis
December 11, 2025
Lacticaseibacillus rhamnosus MS27 Potentially Prevents Ulcerative Colitis Through Modulation of Gut Microbiota.
(PubMed, Int J Mol Sci)
- "(3) L. rhamnosus MS27 exhibits high acid tolerance at pH 3.23 and maintains a high viable bacterial count for 24 h. It can utilize sucrose, lactose, maltose, inulin, esculin, salicin, and mannitol but not raffinose, and it is sensitive to carbenicillin, erythromycin, tetracycline, chloramphenicol, clindamycin, and penicillin. rhamnosus MS27 exhibits distinctive metabolic characteristics in lactic acid utilization, acetic acid and oleic acid production. Furthermore, it contributes to systemic homeostasis regulation by modulating Turicibacter to link intestinal microbiota composition with host immune function."
Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
December 11, 2025
Challenges and Management Outcomes of Osteoarticular Infections in Adult Sickle Cell Disease Patients.
(PubMed, J Clin Med)
- "Most patients were managed conservatively (93.5%), primarily with clindamycin and ciprofloxacin, for approximately six weeks, resulting in an excellent cure rate of 96.8%. The current study highlights the specific clinical features of osteoarticular infections in adult patients with SCD, identifies radiological findings on Magnetic Resonance Imaging, and suggests a conservative, non-invasive approach for management with excellent outcomes."
Journal • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Inflammation • Rheumatology • Sickle Cell Disease
December 10, 2025
Antibiotic-Adjuvants Abolish Resistance Conferred by the Staphylococcus aureus Erythromycin Resistance Methyltransferase in an Escherichia coli Model.
(PubMed, ACS Infect Dis)
- "Assessment of test compounds using this resistance model revealed candidates that displayed promising adjuvant activity when combined with erythromycin or clindamycin. Competition experiments suggested that JNAL-016 competes with SAM for its binding pocket on the enzyme, and this compound exhibited no toxicity against human embryonic kidney cells. These findings establish a practical strategy for targeting Erm-mediated resistance, which could lead to a viable adjuvant-based therapy against bacterial pathogens that weaponize variants of this class of methyltransferases."
Journal
December 10, 2025
The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study.
(PubMed, Elife)
- "Outcomes were Shannon diversity and relative abundance of specific bacterial taxa (Enterobacteriaceae, Enterococcus, and major anaerobic groups) and antimicrobial resistance genes (targeting beta-lactams, tetracyclines, aminoglycosides, macrolides, and glycopeptides)...In contrast, co-trimoxazole, doxycycline, antifungals, and antivirals had less impact on microbiome diversity and selection of AMR genes...Some drugs in the WHO Access group (co-amoxiclav, clindamycin) had similar magnitude impact on microbiome diversity to those in the Watch group (meropenem, piperacillin-tazobactam) with potential implications for acquisition of resistant organisms. Metagenomic sequencing can be used to compare the impact of different antimicrobial agents and treatment strategies on the commensal flora."
Journal • Observational data • Infectious Disease • Transplantation
December 10, 2025
Topical retinoid use in women of reproductive age and risk of major congenital malformations in exposed pregnancies - a Nordic cohort study.
(PubMed, Br J Dermatol)
- "We observed a 3.3-fold increase in topical retinoid use over the past 18 years among women of reproductive age in the Nordic countries. We did not observe an increased risk of MCM associated with use of topical retinoids. Limiting to pregnancies resulting in a birth could underestimate both the prevalence of topical retinoid exposure and MCM risk."
Journal • Acne Vulgaris
December 10, 2025
Identification of Genetic and Environmental Factors Suppressing the Lethality and Antibiotic Susceptibility Mediated by Depletion of LptD, a Lipopolysaccharide Transport Protein.
(PubMed, J Microbiol Biotechnol)
- "Decreased expression of LptD strongly increased susceptibility to several antibiotics, such as clindamycin and rifampicin, and these increased susceptibilities were partially weakened by the deletion of aceE or ygfB. Collectively, these results can improve our understanding of the physiological functions and clinical importance of LptD."
Journal • Infectious Disease
December 09, 2025
The prevalence and molecular epidemiology of Clostridioides difficile in hospital-based pediatric populations in China.
(PubMed, Emerg Microbes Infect)
- "High resistance to clindamycin (64.5%) was observed, primarily mediated by ermB, while all isolates remained susceptible to metronidazole and vancomycin. Moxifloxacin resistance (10.7%) was associated with gyrA T82I mutations, particularly in toxigenic ST3 strains...Genomic relatedness (≤2 SNPs) was detected in 12.0% of asymptomatic carriers, with most links associated with hospital-wide contact, suggesting possible transmission events. This study highlights the importance of asymptomatic colonized children as a reservoir for C. difficile, maintaining resistant lineages and disseminating AMR, thereby underscoring the need for enhanced surveillance and targeted antimicrobial stewardship in Chinese healthcare settings."
Journal • Infectious Disease • Pediatrics
December 09, 2025
Characterization of Methicillin-Resistant Staphylococcus Aureus Resistance and Hematological Profiles in Diabetic Foot Infections.
(PubMed, Clin Lab)
- "This study examined the characteristics of DFU-associated MRSA infection, particularly its multidrug resistance features. MRSA infection demonstrated 100% sensitivity to vancomycin and linezolid. The findings suggest that combined detection of MCHC, D-dimer, ALB, ALP, Na+, Cl-, and Ca2+ may serve as a valuable reference for the early identification of DFU-associated MRSA infection in clinical settings. Clinicians should be mindful of MRSA infection risks in patients with DFU and develop individualized anti-infection regimens based on drug sensitivity profiles to improve prognosis."
Journal • Retrospective data • Hematological Disorders • Infectious Disease
December 09, 2025
NextGen - Clinical Implication of Next Generation Sequencing
(clinicaltrials.gov)
- P4 | N=100 | Recruiting | Sponsor: Wake Forest University Health Sciences | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2028
Biomarker • Trial completion date • Trial primary completion date • Infectious Disease • Nephrology
1 to 25
Of
3854
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155